Interim Report 1 January – 30 June 2024
Good growth in both Business Areas and continued profitability improvement "The companies within AddLife showed strong performance development during the quarter. In Labtech, sales growth recovered as expected and margins remained stable. Sales growth in Medtech was good and margins improved partly driven by restructuring efforts that are now yielding clear results. Cash flow improved significantly and after the end of the quarter, an acquisition was made in line with our updated long-term strategy."Fredrik Dalborg, President and CEO AddLife´s interim report for Q2 2024 is now